Melissa Baird Sells 67,687 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 67,687 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $29.35, for a total transaction of $1,986,613.45. Following the completion of the sale, the chief operating officer now directly owns 706,872 shares in the company, valued at approximately $20,746,693.20. The trade was a 8.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Melissa Baird also recently made the following trade(s):

• On Tuesday, December 10th, Melissa Baird sold 85,561 shares of Hims & Hers Health stock. The stock was sold at an average price of $31.01, for a total transaction of $2,653,246.61.
• On Monday, November 18th, Melissa Baird sold 58,750 shares of Hims & Hers Health stock. The stock was sold at an average price of $21.04, for a total transaction of $1,236,100.00.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $30.89 on Friday. Hims & Hers Health, Inc. has a one year low of $8.51 and a one year high of $35.02. The firm’s 50 day simple moving average is $28.22 and its two-hundred day simple moving average is $22.17. The stock has a market capitalization of $6.75 billion, a P/E ratio of 70.20 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. During the same quarter last year, the business earned ($0.04) earnings per share. The business’s revenue was up 77.1% on a year-over-year basis. As a group, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley assumed coverage on shares of Hims & Hers Health in a report on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price target on the stock. Deutsche Bank Aktiengesellschaft raised their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. TD Cowen reaffirmed a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th. BTIG Research initiated coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price on the stock. Finally, Canaccord Genuity Group raised their target price on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Hims & Hers Health presently has an average rating of “Hold” and an average target price of $25.13.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Raleigh Capital Management Inc. grew its holdings in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 1,100 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Hims & Hers Health by 2,173.7% in the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after purchasing an additional 2,152 shares during the last quarter. Quest Partners LLC grew its holdings in shares of Hims & Hers Health by 22.6% in the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after purchasing an additional 807 shares during the last quarter. CWM LLC grew its holdings in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in Hims & Hers Health by 115.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company’s stock valued at $110,000 after acquiring an additional 2,442 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.